52 results on '"Spada F."'
Search Results
2. Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study
3. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists
4. Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis
5. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms
6. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors
7. Treatments for colorectal liver metastases: A new focus on a familiar concept
8. Model output statistics cascade to improve day ahead solar irradiance forecast
9. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
10. 1160P An Italian multicenter phase II trial of metronomic temozolomide in unfit patients with advanced neuroendocrine neoplasms: Interim analysis of the MeTe study
11. 1159P Molecular characterization of extra-pulmonary mixed adeno-neuroendocrine carcinomas: The NIRVANA substudy
12. 1149MO Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumours and carcinoid syndrome: A retrospective experience of two centers of excellence
13. P2.21-06 Characterization of the Genomic and Immune Landscape of Malignant Pleural Mesothelioma
14. 1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
15. 2293P Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
16. 1199P MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
17. 899P Molecular characterization of gastro-entero-pancreatic advanced mixed adeno-neuroendocrine carcinomas: NIRVANA sub-study
18. PO-19: Venous and arterial thromboembolism in pancreatic neuroendocrine neoplasms
19. Synthesis, characterization and DNA binding affinities of water-soluble benzoheterocycle triosmium clusters
20. 1104P Functional imaging and clinical outcomes in grade 3 neuroendocrine tumors (NETs G3): A single-center retrospective analysis
21. 1097O The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
22. PCN168 Lutetium (177LU) Oxodotreotide Versus Standard of Care in Adult Patients with Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): A Cost-Consequences Analysis from an Italian Hospital Perspective
23. 1184P A single-center retrospective analysis of patients with advanced G3 neuroendocrine tumours
24. 1172P Extra-pulmonary neuroendocrine carcinomas: A single-center retrospective analysis
25. 1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results
26. 1089P POD1UM-201: A phase II study of retifanlimab (INCMGA00012) in advanced or metastatic Merkel cell carcinoma (MCC)
27. 1318P - Carboplatin (CB) combined with oral or intravenous (IV) etoposide (ET) for advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC): Real-world findings from two European neuroendocrine tumour society centres of excellence
28. 448P - Bone metastases in patients with neuroendocrine neoplasms: A survey of natural history and clinical management
29. High-risk human papillomavirus in anal squamous cell carcinoma: a ‘conservative’ leading role
30. 443P - Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)
31. 417O - Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
32. S25 - Real-word analysis on the use of somatostatin analogs (SSAs) in patients with neuroendocrine neoplasms (NENs): results of a survey conducted by the Italian Society of Medical Oncology (AIOM)
33. B17 - Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs)
34. B22 - Appendiceal neuroendocrine tumors: a large multicentre Italian series. Preliminary result
35. B06 - Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
36. R39 - Diffusion-MRI and angiogenic profiling in patients with advanced well-differentiated pancreatic neuroendocrine tumors treated with everolimus
37. R20 - Carboplatin and etoposide chemotherapy in extrapulmonary poorly differentiated neuroendocrine carcinomas
38. R01 - Phase II study of everolimus in combination with octreotide LAR as first line setting for patients with neuroendocrine tumors (I.T.M.O. study): a 5-years update
39. 2344 Angiogenic profiling in patients with advanced well-differentiated pancreatic neuroendocrine tumors treated with everolimus
40. 1150P - Real-World Study on Oxaliplatin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms : Clinical Outcomes and Preliminary Correlation with Biological Factors
41. Progesterone Receptor Up-regulation Following In-Vitro Oestrogen Treatment
42. OXT Gene Up-regulation in Bovine Skeletal Muscle Induced by Dexamethasone and 17β-Oestradiol
43. La perte de sommeil entraîne une altération de la liaison des facteurs de transcriptions circadiens à l’ADN
44. La perte de sommeil entraîne une altération de la liaison des facteurs de transcriptions circadiens à l’ADN
45. P.113 RISK AND PROTECTIVE FACTORS FOR MIDGUT CARCINOID TUMOURS: MULTICENTER CASE-CONTROL STUDY OF PROSPECTIVELY EVALUATED PATIENTS
46. OC1.06.5 ENTEROTOXICITY BY CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH CANCER EVALUATED WITH CAPSULE ENDOSCOPY
47. Bladder endometriosis or adenomyosis
48. Anisotropic and high magnetization rare earth transition metal compounds containing metalloids
49. Catalytic activity of metal hydrides
50. Hydrogen absorption in La 3Ni 13B 2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.